Table 4 Comparison between the VS and non-VS groups (univariate analysis)
VS group (n = 31) | Non-VS group (n = 154) | P-value* | |
|---|---|---|---|
Sex (male:female) | 4:27 | 2:146 | 0.11 |
Age (years) (IQR) | 67 (63−72) | 68 (61−75) | 0.36 |
Age of onset (years) (IQR) | 48 (38−56) | 55 (44−66) | < 0.01 |
RA duration (years) (IQR) | 18 (13−25) | 9 (4−21) | < 0.01 |
CRP level (mg/dL) (IQR) | 0.7 (0.4−1.5) | 0.3 (0.1−1.0) | < 0.01 |
RF positive (n) | 55 % (17/31) | 64 % (98/154) | 0.36 |
MMP3 positive (n) | 61 % (19/31) | 66 % (102/154) | 0.60 |
DAS28-CRP (IQR) | 2.9 (2.2−3.6) | 2.2 (1.7−3.0) | 0.55 |
RA stage III or IV (n) | 97 % (30/31) | 64 % (99/154) | < 0.01 |
Prednisolone (n) | 68 % (21/31) | 45 % (69/154) | 0.02 |
MTX (n) | 52 % (16/31) | 65 % (100/154) | 0.16 |
Biological agents (n) | 42 % (13/31) | 28 % (43/154) | 0.12 |
BMD of the lumbar spine (IQR) | 79 % (74−92) | 82 (71−93) | 0.66 |
BMD of the femoral neck (IQR) | 60 % (49–67) | 68 (60–77) | 0.04 |
Previous joint surgery (n) | 68 % (21/31) | 26 % (40/154) | < 0.01 |